rs121913364
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
|
26422023 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thyroid neoplasms with PD-L1 expression also ae enriched with BRAF V600E mutations, suggesting that they are associated with more aggressive behavior.
|
31821747 |
2020 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thyroid neoplasms with PD-L1 expression also ae enriched with BRAF V600E mutations, suggesting that they are associated with more aggressive behavior.
|
31821747 |
2020 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In thyroid cancer, TPO expression is decreased partly by the BRAF(V600E) mutation, with direct impact on significant hormone production.
|
30742860 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In thyroid cancer, TPO expression is decreased partly by the BRAF(V600E) mutation, with direct impact on significant hormone production.
|
30742860 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The T1799A activating point mutation is detected in >98% of the thyroid tumors, and result in substitution of amino acid valine at position 600 to glutamic acid.
|
30414980 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor characterized by frequent RAS mutations and an absence of the BRAF V600E mutation commonly seen in classical papillary thyroid carcinoma (cPTC).
|
29396809 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was detected in the PTCs of the two patients with thyroid cancer.
|
29593792 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, the present study demonstrated that thyroid cancer harboring the BRAF V600E mutation was resistant to a selective BRAF inhibitor due to reactivation of the MAPK pathway.
|
29616135 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors.
|
29435002 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor characterized by frequent RAS mutations and an absence of the BRAF V600E mutation commonly seen in classical papillary thyroid carcinoma (cPTC).
|
29396809 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors.
|
29435002 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, the present study demonstrated that thyroid cancer harboring the BRAF V600E mutation was resistant to a selective BRAF inhibitor due to reactivation of the MAPK pathway.
|
29616135 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was detected in the PTCs of the two patients with thyroid cancer.
|
29593792 |
2018 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
|
27880942 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This represents a novel mechanism in BRAF V600E-promoted PTC aggressiveness and identifies WIPF1 as a novel therapeutic target for thyroid cancer.
|
27863429 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BM probe not only enabled sensitive detection of two types of EGFR-associated point mutations located in GC-rich regions, but also successfully identified the BRAF V600E mutation in the serum from a thyroid cancer patient which could not be detected by the conventional sequencing method.
|
28201758 |
2017 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Molecular methods can also be applied as rule-out tests for malignancy in thyroid nodules, eg Afirma or ThyroSeq v2 or as markers of prognosis, eg TERT promoter mutation or other gene mutations including BRAF V600E, TP53 and AKT1, and as tests for newly defined tumour entities such as non-invasive follicular thyroid neoplasm with papillary like nuclei, or as a molecular marker(s) for targeted therapies.
|
29165888 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
|
27880942 |
2017 |